
Expres²ion will present its malaria and breast cancer vaccine research at two scientific events in June

Expres²ion Biotech Holding AB and its affiliate Expres²ion Biotechnologies ApS ("Expres²ion") announce that the Company will hold presentations at an annual meeting hosted by the World Biopharm Forum in Oxford, UK, June 20-22 and at the Vaccine Technology VII Meeting in Mont Tremblant, Quebec, Canada, June 17-22.

"These events will let us present Expres²ion's globally acknowledged platform for developing and producing vaccines that can be used for both infectious diseases and novel cancer treatments. As we are at the forefront in developing promising vaccines for large patient groups, there is a lot of interest in our work from the scientific community as well as from pharmaceutical companies in different parts of the world," says Expres²ion's CEO Dr. Steen Klysner.

Malaria vaccine presentation at the World Biopharm Forum Event

The World Biopharm Forum is arranging the Annual Meeting on Continuous Biomanufacturing: Achievements and Challenges for Commercial Implementation at the University of Oxford, UK, on June 20-22, 2018.

This meeting provides an opportunity to share Expres²ion's protein bioprocessing experience with a great multidisciplinary team of leading international scientists, technologists, engineers and others from across the world. Expres²ion's CSO Dr. Wian de Jongh will be presenting at 4.00pm GMT on June 21st, 2018, under the headline "*Impact of continuous/intensified production towards a cost-effective malaria vaccine*".

More information on the conference can be found here:

http://www.subramanian.org.uk/Programmes/World%20Biopharm%202018_final.pdf

Breast cancer vaccine and malaria vaccine presentations at the Vaccine Technology VII Meeting

The Vaccine Technology VII Meeting will take place on June 17-22, in Mont Tremblant, Quebec, Canada.

Thomas Jorgensen, Scientist & Project Manager at Expres²ion, will hold the presentation "*HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing with a novel VLP-display technology*". He will also hold a poster presentation entitled "*A clinically validated Drosophila S2 based vaccine platform for production of malaria vaccines*".

The meeting is organised by scientists from academia and industry through Engineering Conferences International, and it differentiates itself from commercial conferences by providing very high quality, cutting-edge scientific content. Many national and international organisations including The Bill and Melinda Gates Foundation as well as the vaccine industry have supported the previous meetings in this series.

More information on the conference can be found here:

<http://www.engconf.org/conferences/biotechnology/vaccine-technology-vii/>

Certified Adviser

Sedermera Fondkommission is appointed as Certified Adviser for Expres²ion.

For further information about Expres²ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: sk@expres2ionbio.com

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS², that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS²ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.